Challenges in Biosimilar Pharmacovigilance

This session of the Biosimilars 2018 will investigate the future and FDA activities that have just been reported to incorporate upgraded following and follow-up of post showcasing reconnaissance issues, arranged enhancements in AERS, and pilots of new post advertise sedate observing procedures and ADR related issues. Biosimilar rules for pharmacovigilance practice and pharmacoepidemiology are the focuses that might be laid accentuation in this session.